Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X6BX
|
|||
| Former ID |
DNCL002381
|
|||
| Drug Name |
ABC294640
|
|||
| Synonyms |
ABC294640; 915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8; ABC294640; 915385-81-8; ABC-294640
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 3 | [1], [2] | |
| Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 2 | [3] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [3] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [3] | ||
| Company |
Apogee Biotechnology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25ClN2O
|
|||
| Canonical SMILES |
C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
|
|||
| InChI |
1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
|
|||
| InChIKey |
CAOTVXGYTWCKQE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 915385-81-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:124965
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine kinase 2 (SPHK2) | Target Info | Modulator | [4], [5], [6] |
| BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| VEGF signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Tuberculosis | ||||
| Panther Pathway | Angiogenesis | |||
| VEGF signaling pathway | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Ceramide signaling pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| Reactome | Sphingolipid de novo biosynthesis | |||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Sphingolipid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6624). | |||
| REF 2 | ClinicalTrials.gov (NCT02229981) An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. | |||
| REF 5 | Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.J Exp Clin Cancer Res.2015 Sep 4;34:94. | |||
| REF 6 | The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.Cell Signal.2013 Apr;25(4):1011-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.